Clinical Study On Changes Of Soluble Lectin-like Oxidized Low-density Lipoprotein Receptor–1(sLOX-1) Levels Of Early Rosuvastatin Therapy With Different Doses In Patients With Acute Coronary Syndromes

Objective: To evaluate the effect of rosuvastatin medication with different doses on serum level of soluble lectin-like oxidized low-density lipoprotein receptor-1(s LOX-1)in patients with acute coronary syndrome(ACS)Methods:Patients(n=80)with ACS were randomly assigned into rosuvastatin 10 mg group(40mg loading dose and 10 mg·d-1,RSV10 group,n=40)and rosuvastatin 5mg group(5mg·d-1,RSV5 group,n=40).Everyone was detected the level of Hs-CRP and TC,LDL, HDL before treated with rosuvastatin. All patients were accepted based on the clinical situation,including coronary revascularization,and aspirin,clopidogrel hydrogen, tirofiban,low molecular weight heparin,ACEI/ARB,β-blockers,calcium channel blockers, nitric acid esters drugs,diuretics and other basic drugs. Major adverse cardiac events( MACE) were observed during hospitalization,monitoring of adverse drug reactions. Serum s LOX-1 levels of immediate admission and the third day were determinated using enzyme-linked immunosorbent assay and were compared between groups.Results: 1. No significant differences were observed in the baseline clinical characteristics,coronary risk profiles such as sex ratio,mean age,smoking,hypertension and diabetes mellitus,further including PCI surgical history and the number of coronary artery diseased vessels in both groups(P>0.05). 2. The density of s LOX-1 in the third day during hospitalization is(290.03±141.43)pg/ml in RSV10 group,which remarkablely decreases in comparison with the value of(397.86±170.61)pg/ml on admission. Reduce of the rate is 27.1%(t=4.625,P<0.001);The density of s LOX-1 in the third day during hospitalization is(300.03±135.31)pg/ml in RSV5 group. The value of s LOX-1 declined significantly as well compared with( 385.66 ± 154.39) pg/ml on admission,and the reduction is 22.2%(t=3.329,P<0.05);The comparison of the s LOX-1 density between groups on admission has no significance(t=-0.335,P=0.739);The reduction has no significance as well between the two groups(t=-0.639,P=0.525).3. No differentiation were found out between the two groups of serum lipid levels on immediate admission and the third day of hospitalization(P>0.05); the lipid levels of RSV10 group is lower than RSV5 group after 4 weeks treatment(P<0.05). 4. The rate of MACE during hospitalization in RSV10 group is lower than control group(c2=4.588,P<0.05); 5. There is no adverse drug recation during hospitalization in both two groups.Conclusion: 1. In real-world clinical practice,early rosuvastatin treatment could significantly decrease the serum density of s LOX-1 in patients with ACS,obviously. Besides,the effect showed no dose dependent. 2. Loading-dose and mild moderate-dose statin,which is relatively safe,could reduce the incidence of MACE during hospitalization. 3. s LOX-1 has a predictive value in patients with ACS,possibly as atherosclerotic plaque instability serological markers. 4. Statin therapy can reduce the incidence of MACE during hospitalization,with a dose-dependent manner. 5. During hospitalization,there was no significant adverse reactions occurred in two groups,suggesting that intensive statin treatment had no significant adverse drug reactions.